Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:BCRX NASDAQ:FOLD NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.64-1.6%$28.76$25.17▼$36.45$5.22B0.541.80 million shs684,660 shsBCRXBioCryst Pharmaceuticals$6.37-9.5%$7.98$6.01▼$11.31$1.34B1.053.69 million shs15.22 million shsFOLDAmicus Therapeutics$8.05-1.6%$7.77$5.51▼$12.65$2.48B0.564.07 million shs516,269 shsLGNDLigand Pharmaceuticals$179.96+0.0%$164.61$93.58▼$186.40$3.53B0.95155,687 shs20,455 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+3.08%+3.81%+19.28%+11.51%+11.28%BCRXBioCryst Pharmaceuticals-2.49%+0.28%-11.00%-19.27%-5.25%FOLDAmicus Therapeutics-1.45%+0.25%+2.38%+38.41%-22.10%LGNDLigand Pharmaceuticals+1.22%-1.49%+8.53%+44.72%+74.75%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$31.64-1.6%$28.76$25.17▼$36.45$5.22B0.541.80 million shs684,660 shsBCRXBioCryst Pharmaceuticals$6.37-9.5%$7.98$6.01▼$11.31$1.34B1.053.69 million shs15.22 million shsFOLDAmicus Therapeutics$8.05-1.6%$7.77$5.51▼$12.65$2.48B0.564.07 million shs516,269 shsLGNDLigand Pharmaceuticals$179.96+0.0%$164.61$93.58▼$186.40$3.53B0.95155,687 shs20,455 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+3.08%+3.81%+19.28%+11.51%+11.28%BCRXBioCryst Pharmaceuticals-2.49%+0.28%-11.00%-19.27%-5.25%FOLDAmicus Therapeutics-1.45%+0.25%+2.38%+38.41%-22.10%LGNDLigand Pharmaceuticals+1.22%-1.49%+8.53%+44.72%+74.75%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.93Moderate Buy$42.0032.74% UpsideBCRXBioCryst Pharmaceuticals 2.75Moderate Buy$16.30155.81% UpsideFOLDAmicus Therapeutics 2.82Moderate Buy$15.7896.02% UpsideLGNDLigand Pharmaceuticals 2.71Moderate Buy$176.50-1.92% DownsideCurrent Analyst Ratings BreakdownLatest BCRX, ALKS, LGND, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BCRXBioCryst PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025FOLDAmicus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/6/2025BCRXBioCryst PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/6/2025FOLDAmicus TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/1/2025BCRXBioCryst PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ In-Line$8.009/27/2025ALKSAlkermesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025BCRXBioCryst PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025FOLDAmicus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/26/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSector Perform ➝ Outperform$42.00 ➝ $44.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.35$2.69 per share11.77$9.05 per share3.50BCRXBioCryst Pharmaceuticals$450.71M2.97N/AN/A($2.30) per share-2.77FOLDAmicus Therapeutics$528.29M4.70N/AN/A$0.65 per share12.38LGNDLigand Pharmaceuticals$167.13M21.10$1.63 per share110.61$43.95 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0815.2123.091.6923.15%24.86%17.14%10/23/2025 (Estimated)BCRXBioCryst Pharmaceuticals-$88.88M-$0.18N/AN/A1.45-6.41%N/A-1.78%11/3/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A18.72N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A48.51N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)Latest BCRX, ALKS, LGND, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025LGNDLigand Pharmaceuticals$1.96N/AN/AN/A$58.71 millionN/A11/5/2025Q3 2025FOLDAmicus Therapeutics$0.12N/AN/AN/A$165.24 millionN/A11/3/2025Q3 2025BCRXBioCryst Pharmaceuticals$0.05N/AN/AN/A$162.91 millionN/A10/23/2025Q3 2025ALKSAlkermes$0.41N/AN/AN/A$355.23 millionN/A8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.03$0.15+$0.12$0.02$149.59 million$163.35 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ABCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85BCRXBioCryst PharmaceuticalsN/A2.252.22FOLDAmicus Therapeutics1.923.212.29LGNDLigand PharmaceuticalsN/A5.455.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%BCRXBioCryst Pharmaceuticals85.88%FOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%BCRXBioCryst Pharmaceuticals5.10%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableBCRXBioCryst Pharmaceuticals530209.92 million199.21 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableBCRX, ALKS, LGND, and FOLD HeadlinesRecent News About These CompaniesAberdeen Group plc Has $26.06 Million Holdings in Ligand Pharmaceuticals Incorporated $LGNDOctober 14 at 4:03 AM | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Recommendation of "Moderate Buy" by AnalystsOctober 13 at 2:23 AM | americanbankingnews.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Consensus Rating of "Moderate Buy" by AnalystsOctober 13 at 2:22 AM | marketbeat.comVillere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGNDOctober 11 at 5:46 AM | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comLigand partner SQ Innovation receives approval from FDA for Lasix ONYUOctober 9, 2025 | msn.comLigand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure PatientsOctober 9, 2025 | quiverquant.comQLigand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure PatientsOctober 9, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year High - Here's What HappenedOctober 6, 2025 | marketbeat.comJohn Kozarich Sells 467 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockOctober 4, 2025 | insidertrades.comLigand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 SharesOctober 3, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Purchased by Chicago Capital LLCSeptember 30, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month High - What's Next?September 29, 2025 | marketbeat.comCongress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGNDSeptember 26, 2025 | marketbeat.comJason Aryeh Sells 10,000 Shares of Ligand Pharmaceuticals (NASDAQ:LGND) StockSeptember 25, 2025 | insidertrades.comArecor announces Co-development Agreement with US Insulin Pump Device Company for AT278 & Sale of Royalty Rights and Technology Access Fees for AT220 and AT292September 25, 2025 | globenewswire.comLigand Pharmaceuticals (NASDAQ:LGND) Director Sells $1,708,100.00 in StockSeptember 24, 2025 | marketbeat.comStrs Ohio Invests $789,000 in Ligand Pharmaceuticals Incorporated $LGNDSeptember 20, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 12-Month High - Here's WhySeptember 19, 2025 | marketbeat.comContravisory Investment Management Inc. Takes Position in Ligand Pharmaceuticals Incorporated $LGNDSeptember 19, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Given Average Rating of "Buy" by AnalystsSeptember 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Why the Precious Metal Nobody Talks About Could Be Your Best BetBy Jordan Chussler | October 4, 2025BCRX, ALKS, LGND, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$31.64 -0.53 (-1.65%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.BioCryst Pharmaceuticals NASDAQ:BCRX$6.37 -0.67 (-9.49%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Amicus Therapeutics NASDAQ:FOLD$8.05 -0.13 (-1.60%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$179.96 +0.07 (+0.04%) As of 11:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
